New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.

Authors:
Carmona-Rocha E; Rusiñol L; Puig L.

Journal:
Pharmaceutics

Publication Year: 2024

DOI:
10.3390/pharmaceutics16020239

PMCID:
PMC10892104

PMID:
38399292

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pharmaceutics

Abbreviation: Pharmaceutics

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
3D-Printed Alginate/Pectin-Based Patches Loaded with Olive Leaf Extracts for Wound Healing Applicat…
Patitucci F; Motta MF; Dattilo M and 8 more (2024) - Transparency Score: 3/6
3D Printing of Biodegradable Polymeric Microneedles for Transdermal Drug Delivery Applications.
Aldawood FK; Parupelli SK; Andar A and 1 more (2024) - Transparency Score: 3/6
4-(Phenylselanyl)-2H-chromen-2-one-Loaded Nanocapsule Suspension-A Promising Breakthrough in Pain M…
da Fonseca CAR; Prado VC; Paltian JJ and 10 more (2024) - Transparency Score: 4/6
A Bilayer Microarray Patch (MAP) for HIV Pre-Exposure Prophylaxis: The Role of MAP Designs and Form…
Vora LK; Tekko IA; Zanutto FV and 7 more (2024) - Transparency Score: 3/6
Acylation of Oleanolic Acid Oximes Effectively Improves Cytotoxic Activity in In Vitro Studies.
Bednarczyk-Cwynar B; Ruszkowski P. (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest E.C.-R. has perceived the speaker’s honoraria from Boehringer-Ingelheim and Amgen. L.R. declares no conflicts of interest for the related topic. L.P. has perceived consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Fresenius-Kabi, Gebro, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Novartis, Pfizer, Samsung-Bioepis, and UCB."

Evidence found in paper:

"This research received no external funding."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025